Your browser doesn't support javascript.
loading
Evaluation of two strategies for the interpretation of tumour markers in pleural effusions.
Trapé, Jaume; Sant, Francesc; Franquesa, Josefina; Montesinos, Jesús; Arnau, Anna; Sala, Maria; Bernadich, Oscar; Martín, Esperanza; Perich, Damià; Pérez, Concha; Lopez, Joan; Ros, Sandra; Esteve, Enrique; Pérez, Rafael; Aligué, Jordi; Gurt, Gabriel; Catot, Silvia; Domenech, Montserrat; Bosch, Joan; Badal, Josep Miquel; Bonet, Mariona; Molina, Rafael; Ordeig, Josep.
Afiliación
  • Trapé J; Department of Laboratory Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Dr Joan Soler 1-3, 08243, Manresa, Catalonia, Spain. jtrape@althaia.cat.
  • Sant F; Department of Pathology, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Franquesa J; Department of Laboratory Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Dr Joan Soler 1-3, 08243, Manresa, Catalonia, Spain.
  • Montesinos J; Department of Oncology, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Arnau A; Clinical Research Unit, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Sala M; Department of Laboratory Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Dr Joan Soler 1-3, 08243, Manresa, Catalonia, Spain.
  • Bernadich O; Department of Pulmonary Diseases, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Martín E; Department of Pulmonary Diseases, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Perich D; Department of Pulmonary Diseases, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Pérez C; Department of Pulmonary Diseases, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Lopez J; Department of Laboratory Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Dr Joan Soler 1-3, 08243, Manresa, Catalonia, Spain.
  • Ros S; Department of Pulmonary Diseases, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Esteve E; Department Internal Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Pérez R; Department Internal Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Aligué J; Department Internal Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Gurt G; Polytechnic School of University of Vic, Universitat Central de Catalunya, Vic, Catalonia, Spain.
  • Catot S; Department of Oncology, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Domenech M; Department of Oncology, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Bosch J; Department of Medicine, Universitat Internacional de Catalunya, Sant Cugat, Catalonia, Spain.
  • Badal JM; Department of Pathology, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Bonet M; Department Internal Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
  • Molina R; Laboratory of Biochemistry (Oncobiology Unit), Biomedical Diagnostic Center (CDB), Hospital Clinic, IDIBAPS, University of Barcelona, Catalonia, Spain.
  • Ordeig J; Department Internal Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
Respir Res ; 18(1): 103, 2017 05 25.
Article en En | MEDLINE | ID: mdl-28545517
ABSTRACT

BACKGROUND:

Pleural effusions present a diagnostic challenge. Approximately 20% are associated with cancer and some 50% require invasive procedures to perform diagnosis. Determination of tumour markers may help to identify patients with malignant effusions. Two strategies are used to obtain high specificity in the differential diagnosis of malignant pleural effusions a) high cut-off, and b) fluid/serum (F/S) ratio and low cut-off. The aim of this study is to compare these two strategies and to establish whether the identification of possible false positives using benign biomarkers - ADA, CRP and % of polymorphonuclear cells - improves diagnostic accuracy.

METHODS:

We studied 402 pleural effusions, 122 of them malignant. Benign biomarkers were determined in pleural fluid, and CEA, CA72-4, CA19-9 and CA15-3 in pleural fluid and serum.

RESULTS:

Establishing a cut-off value for each TM for a specificity of 100%, a joint sensitivity of 66.5% was obtained. With the F/S strategy and low cut-off points, sensitivity was 77% and specificity 98.2%, Subclassifying cases with negative benign biomarkers, both strategies achieved a specificity of 100%; sensitivity was 69.9% for single determination and 80.6% for F/S ratio.

CONCLUSIONS:

The best interpretation of TM in the differential diagnosis of malignant pleural effusions is obtained using the F/S ratio in the group with negative benign biomarkers.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Derrame Pleural Maligno Tipo de estudio: Diagnostic_studies / Evaluation_studies / Prognostic_studies Idioma: En Revista: Respir Res Año: 2017 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Derrame Pleural Maligno Tipo de estudio: Diagnostic_studies / Evaluation_studies / Prognostic_studies Idioma: En Revista: Respir Res Año: 2017 Tipo del documento: Article